|1.||Eilon, G F: 1 article (01/2000)|
|2.||Gu, J: 1 article (01/2000)|
|3.||Hara, K: 1 article (01/2000)|
|4.||Slater, L M: 1 article (01/2000)|
|5.||Jacobs, J W: 1 article (01/2000)|
09/01/1982 - "Among these analogues, NCO-700 was the most potent to reduce the size of acute myocardial infarction, which was produced by coronary artery ligation in rabbits, in vivo, although it showed less powerful action to inhibit CANP activity in vitro. "
09/01/1982 - "The new reagent, NCO-700 might be promising to reduce acute myocardial infarction size and beneficial for the clinical studies, because it had no action to reduce cardiac muscle contractility, compared with beta antagonist or calcium-channel blockades."
09/01/1982 - "Reduction of experimentally produced acute myocardial infarction size by a new synthetic inhibitor, NCO-700, against calcium-activated neutral protease."
02/01/1986 - "These data and the myocardial infarction size reducing action of NCO-700 might support the view that NCO-700 sensitive protease(s) - possibly, calcium-activated neutral protease and/or cathepsin B - is (are) working to induce an irreversible proteolysis in the process of myocardial cell degradation."
01/01/2000 - "A final objective of this study was to establish if NCO-700 and TOP-008 achieved cancer cell killing through an apoptotic mechanism. "
01/01/2000 - "When human prostate (DU-145) or breast cancer (HS-578T) cells were grown as solid tumors in the subrenal capsules of mice, significant anti-tumor activity of NCO-700 was observed at 20 mg/kg and 50 mg/kg body weight respectively, for prostate and breast tumors. "
01/01/2000 - "These studies indicated that the epoxide-containing piperazines, as exemplified by NCO-700 and TOP-008, were effective anti-cancer agents when tested in vitro and in vivo against human breast and prostate tumors. "
01/01/2000 - "The anti-proliferative activity of NCO-700 and TOP-008 were tested in a 7 day cell-survival assay utilizing a number of well characterized breast (HS-578T, T47D, MCF-7) and prostate (DU-145, PC-3, LNCaP) cancer cell lines. "
11/01/1985 - "NCO-700, however, did not inhibit the decrease in the content of 55K and AN being induced by ischemia."
11/01/1985 - "Treatment with NCO-700 at the total dose of 20 mg/kg, which was injected intravenously before and during ischemia, inhibited both appearance of the degradation bands and the decrease in the content of A, TM, TN I, LC1 and LC2 being produced by cardiac ischemia. "
01/01/1985 - "However, NCO-700 did not attenuate the ischemia-induced elevation of ST segment of the surface electrocardiogram. "
11/01/1985 - "We examined whether NCO-700 inhibits degradation of myofibrillar proteins induced by cardiac ischemia in dogs anesthetized with pentobarbital. "
11/01/1985 - "Inhibition with NCO-700, a protease inhibitor, of degradation of cardiac myofibrillar proteins during ischemia in dogs."
|5.||Myocardial Ischemia (Ischemic Heart Diseases)
|1.||Calcium Channels (Calcium Channel)
|4.||Protease Inhibitors (Protease Inhibitor)
|7.||Proteins (Proteins, Gene)
|8.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)